Table 1. Summary of compositional comparisons for human proteins.

Mean differences (MD), percent values of common language effect size (ES), and p-values are shown for comparisons between groups of proteins reported to have higher abundance in normal (n₁) or cancer (n₂) tissue (or less advanced or more advanced cancer stages, respectively). The textual descriptions are written such that the ordering around the slash (“/”) corresponds to n₂/n₁. References and specific abbreviations used in the descriptions are given in ‘Data sources’.

Reference (Description)	n1	n2	ZC			${\overline{n}}_{{\mathrm{H}}_2\mathrm{O}}$
			MD	ES	p-value	MD	ES	p-value
WTK+08 (T/N)	57	70	0.018	55	3e–01	0.006	52	7e–01
AKP+10 (CRC nuclear matrix C/A)	101	28	−0.012	47	7e–01	−0.009	48	8e–01
AKP+10 (CIN nuclear matrix C/A)	87	81	−0.031	40	3e–02	0.006	48	7e–01
AKP+10 (MIN nuclear matrix C/A)	157	76	−0.002	52	7e–01	−0.013	45	3e–01
JKMF10 (serum biomarkers up/down)	43	56	−0.007	46	5e–01	0.056	67	4e–03
XZC+10 (stage I/normal)	48	166	0.009	52	7e–01	0.026	56	2e–01
XZC+10 (stage II/normal)	77	321	0.022	60	6e–03	0.018	54	3e–01
ZYS+10 (microdissected T/N)	60	57	0.019	58	1e–01	0.022	58	1e–01
BPV+11 (adenoma/normal)	71	92	−0.023	40	4e–02	0.004	49	8e–01
BPV+11 (stage I/normal)	109	72	-0.007	47	5e–01	0.005	50	9e–01
BPV+11 (stage II/normal)	164	140	0.031	62	3e–04	0.006	51	7e–01
BPV+11 (stage III/normal)	63	131	0.025	62	9e–03	−0.005	47	5e–01
BPV+11 (stage IV/normal)	42	26	−0.010	44	4e–01	0.005	52	8e–01
JCF+11 (T/N)	72	45	0.032	63	2e–02	−0.003	49	8e–01
MRK+11 (adenoma/normal)	335	288	0.011	54	1e–01	0.058	68	2e–15
MRK+11 (adenocarcinoma/adenoma)	373	257	0.034	65	1e–10	−0.009	47	1e–01
MRK+11 (adenocarcinoma/normal)	351	232	0.034	63	4e–08	0.035	61	8e–06
KKL+12 (poor/good prognosis)	75	61	0.026	64	5e–03	−0.002	48	8e–01
KYK+12 (MSS-type T/N)	73	175	0.024	61	9e–03	0.023	56	1e–01
WOD+12 (T/N)	79	677	0.016	54	2e–01	0.027	58	2e–02
YLZ+12 (conditioned media T/N)	55	68	0.024	61	4e–02	0.009	54	5e–01
MCZ+13 (stromal T/N)	33	37	0.047	74	5e–04	−0.034	42	2e–01
KWA+14 (chromatin-binding C/A)	51	55	−0.039	29	2e–04	−0.010	48	7e–01
UNS+14 (epithelial adenoma/normal)	58	65	0.001	49	8e–01	0.032	61	4e–02
WKP+14 (tissue secretome T/N)	44	210	0.006	53	6e–01	0.057	68	1e–04
STK+15 (membrane enriched T/N)	113	66	0.005	52	6e–01	0.025	55	2e–01
WDO+15 (adenoma/normal)	1,061	1,254	0.030	64	7e–33	0.023	58	7e–11
WDO+15 (carcinoma/adenoma)	772	1,007	−0.013	42	2e–08	−0.003	50	7e–01
WDO+15 (carcinoma/normal)	879	1,281	0.014	57	9e–08	0.024	58	1e–10
LPL+16 (stromal AD/NC)	123	75	−0.039	32	2e–05	0.037	60	2e–02
LPL+16 (stromal CIS/NC)	125	60	−0.007	46	4e–01	−0.001	52	7e–01
LPL+16 (stromal ICC/NC)	99	75	0.001	47	6e–01	−0.021	48	7e–01
PHL+16 (AD/NC)	113	86	0.011	54	4e–01	0.037	60	2e–02
PHL+16 (CIS/NC)	169	138	0.019	59	5e–03	0.001	49	7e–01
PHL+16 (ICC/NC)	129	100	0.016	57	6e–02	−0.007	46	3e–01

Notes.

Abbreviations

T/N

tumor/normal

C/A

carcinoma/adenoma